AU2018205217B2 - Topical detomidine formulations - Google Patents

Topical detomidine formulations Download PDF

Info

Publication number
AU2018205217B2
AU2018205217B2 AU2018205217A AU2018205217A AU2018205217B2 AU 2018205217 B2 AU2018205217 B2 AU 2018205217B2 AU 2018205217 A AU2018205217 A AU 2018205217A AU 2018205217 A AU2018205217 A AU 2018205217A AU 2018205217 B2 AU2018205217 B2 AU 2018205217B2
Authority
AU
Australia
Prior art keywords
detomidine
topical
formulation
formulations
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018205217A
Other languages
English (en)
Other versions
AU2018205217A1 (en
Inventor
Omer Tsipori
Mark ZAMANSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clexio Bioscience Ltd
Original Assignee
Clexio Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clexio Bioscience Ltd filed Critical Clexio Bioscience Ltd
Publication of AU2018205217A1 publication Critical patent/AU2018205217A1/en
Application granted granted Critical
Publication of AU2018205217B2 publication Critical patent/AU2018205217B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018205217A 2017-01-06 2018-01-05 Topical detomidine formulations Active AU2018205217B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443174P 2017-01-06 2017-01-06
US62/443,174 2017-01-06
PCT/US2018/012579 WO2018129313A1 (en) 2017-01-06 2018-01-05 Topical detomidine formulations

Publications (2)

Publication Number Publication Date
AU2018205217A1 AU2018205217A1 (en) 2019-05-23
AU2018205217B2 true AU2018205217B2 (en) 2023-11-09

Family

ID=61054537

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018205217A Active AU2018205217B2 (en) 2017-01-06 2018-01-05 Topical detomidine formulations

Country Status (15)

Country Link
US (2) US20190343805A1 (enExample)
EP (1) EP3565526B1 (enExample)
JP (1) JP2020505322A (enExample)
KR (1) KR20190110561A (enExample)
CN (1) CN110114059A (enExample)
AU (1) AU2018205217B2 (enExample)
BR (1) BR112019011961A2 (enExample)
CA (1) CA3049389A1 (enExample)
DK (1) DK3565526T3 (enExample)
ES (1) ES2982022T3 (enExample)
HU (1) HUE068070T2 (enExample)
IL (1) IL266448B2 (enExample)
MX (1) MX382949B (enExample)
PL (1) PL3565526T3 (enExample)
WO (1) WO2018129313A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020012415A2 (en) * 2018-07-11 2020-01-16 Clexio Biosciences Ltd. Topical detomidine formulations
WO2020016827A1 (en) * 2018-07-18 2020-01-23 Clexio Biosciences Ltd. Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052347A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Transmucosale und transdermale arzneimittel mit verbesserter wirkstoffresorption
WO2006048501A1 (en) * 2004-11-05 2006-05-11 Orion Corporation A transmucosal veterinary composition comprising detomidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127586A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Topical treatments for pain
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
EP2803668A1 (en) * 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CA2921221A1 (en) * 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052347A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Transmucosale und transdermale arzneimittel mit verbesserter wirkstoffresorption
WO2006048501A1 (en) * 2004-11-05 2006-05-11 Orion Corporation A transmucosal veterinary composition comprising detomidine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YING JIN ET AL: "Ocular Hypotensive Effects of Medetomidine and Its Analogs", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS., vol. 7, no. 4, 1 January 1991 (1991-01-01), US, pages 285 - 296. *

Also Published As

Publication number Publication date
WO2018129313A1 (en) 2018-07-12
IL266448A (en) 2019-06-30
MX382949B (es) 2025-03-13
ES2982022T3 (es) 2024-10-14
JP2020505322A (ja) 2020-02-20
US20230172909A1 (en) 2023-06-08
IL266448B1 (en) 2023-07-01
EP3565526B1 (en) 2024-04-17
MX2019008115A (es) 2019-10-24
CN110114059A (zh) 2019-08-09
US20190343805A1 (en) 2019-11-14
EP3565526A1 (en) 2019-11-13
CA3049389A1 (en) 2018-07-12
IL266448B2 (en) 2023-11-01
PL3565526T3 (pl) 2024-09-09
BR112019011961A2 (pt) 2019-11-05
AU2018205217A1 (en) 2019-05-23
KR20190110561A (ko) 2019-09-30
DK3565526T3 (en) 2024-05-13
HUE068070T2 (hu) 2024-12-28

Similar Documents

Publication Publication Date Title
US20230172909A1 (en) Topical detomidine formulations
US8609722B2 (en) Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine
US9415108B2 (en) Compositions for transdermal delivery of active agents
US11865217B2 (en) Transdermal drug delivery system
KR20030009385A (ko) 국소 마취제의 국소 투여를 위한 피내 침투제
JP2009542657A (ja) ゲルの形態でのロピニロール含有薬学的組成物、その使用
KR20190060007A (ko) 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
CA3072849A1 (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel
US20180369136A1 (en) Devices and methods for transdermal treatment of basal cell carcinoma
CN107921137A (zh) 组合物和治疗方法
JP2022531116A (ja) そう痒症を治療する方法
KR20080097420A (ko) 티오우레아 유도체를 함유하는 소양성 또는 자극성피부질환의 예방 또는 치료용 외용제 조성물
CN110402142A (zh) 含局麻药的酸性乳液组合物
JP7257378B2 (ja) 水中油型エマルション
US20220305076A1 (en) Topical cyclosporine for treating psoriasis and other ailments
JP6016085B2 (ja) 抗真菌外用組成物及び抗真菌外用組成物の適用方法
US20250195413A1 (en) Compositions and methods for treating hair loss
AU2015277554A1 (en) Transdermal formulations of pergolide and uses thereof
HK40013621A (en) Acidic emulsion composition containing local anesthetic agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)